Bolt Biotherapeutics (BOLT) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Skye Bioscience is the larger company by market cap ($7.4 million vs $7.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLT | SKYE |
|---|---|---|
| Share price | $3.65 | $1.68 |
| Market cap | $7.03M | $7.44M |
| 1-day change | +1.39% | +1.82% |
| EPS (TTM) | $-16.28 | $-10.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.20 | $14.08 |
| 52-week low | $3.10 | $1.50 |
| Distance from 52-week high | -49.31% | -88.07% |
| Analyst consensus | none | none |
| Avg. price target upside | +694.52% | +3947.62% |
| Average volume | 26.26K | 89.28K |
| Shares outstanding | 1.93M | 4.43M |
| Employees | 23 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Healthcare · Biotechnology · 23 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Healthcare · Biotechnology · 2 employees
BOLT vs SKYE FAQ
Which is bigger, Bolt Biotherapeutics or Skye Bioscience?
Skye Bioscience (SKYE) is larger, with a market capitalization of $7.44M compared with $7.03M for Bolt Biotherapeutics (BOLT).
Are Bolt Biotherapeutics and Skye Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.